NCT07314138

Brief Summary

The MICRA-HYBRID trial is a prospective, multicenter, randomized controlled study comparing multivessel hybrid coronary revascularization (HCR) as minimally invasive arterial bypass grafting to left-sided coronary targets (LAD and LCx) plus PCI of the RCA versus conventional off-pump coronary artery bypass grafting (OPCAB) via median sternotomy in patients with three-vessel coronary artery disease. The primary goal is to evaluate whether multivessel-HCR provides superior 30-day "textbook" clinical outcomes (mortality, MI, stroke, re-exploration for bleeding, and other complications) while improving perioperative recovery and long-term cardiovascular outcomes.

Trial Health

67
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for not_applicable

Timeline
97mo left

Started Apr 2026

Longer than P75 for not_applicable

Geographic Reach
2 countries

2 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
Apr 2026May 2034

First Submitted

Initial submission to the registry

December 3, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 2, 2026

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2029

Expected
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2034

Last Updated

January 2, 2026

Status Verified

December 1, 2025

Enrollment Period

3.1 years

First QC Date

December 3, 2025

Last Update Submit

December 23, 2025

Conditions

Keywords

minimally invasive coronary surgerypercutaneous coronary interventionoff-pump coronary artery bypass graftinghybrid coronary revascularizationheart surgery

Outcome Measures

Primary Outcomes (1)

  • Composite Absence of Adverse Events within 30 Days Postoperatively (Textbook Outcome)

    The primary endpoint is defined as the "Textbook Outcome," which is the composite absence, within 30 days postoperatively, of the following events: * Mortality * Re-exploration for bleeding * Postoperative ischemia (requiring bypass grafting or acute PCI) * Postoperative myocardial infarction (type 5 MI according to the fourth universal definition of myocardial infarction) * Cardiac tamponade (requiring surgical or percutaneous intervention) * Cerebrovascular accident / transient ischemic attack * Wound infection requiring antibiotics or intervention * New-onset atrial fibrillation requiring medical anti-thrombotic therapy * Pneumonia requiring IV or oral antibiotics * Placement of additional chest drains * Prolonged hospital stay (\> 7 days) after surgery

    30 days postoperatively

Secondary Outcomes (15)

  • Conversion to Sternotomy

    Peri-operatively

  • Conversion to Cardiopulmonary Bypass

    Peri-operatively

  • Intensive Care Unit (ICU) Stay

    30 days postoperatively

  • Postoperative Hospital Stay

    30 days postoperatively

  • Mechanical Ventilation Time

    30 days postoperatively

  • +10 more secondary outcomes

Study Arms (2)

Multivessel hybrid coronary revascularization (HCR)

ACTIVE COMPARATOR

Minimally invasive coronary artery bypass surgery to the left sided coronary vessels combined with percutaneous coronary intervention to the right coronary artery.

Procedure: Multivessel Hybrid Coronary Revascularization

Off-pump coronary artery bypass grafting (OPCAB)

ACTIVE COMPARATOR

Total arterial, anaortic off-pump ccoronary artery bypass grafting through median sternotomy.

Procedure: Off-pump coronary arterial bypass grafting (OPCAB)

Interventions

Multivessel-HCR consists of MICS revascularization of the left sided coronary vessels (LAD , Cx) combined with PCI for the RCA during the same admission or within 4 weeks postoperatively. Surgical revascularization is performed through MICS which consists of either robotically or non-robotically assisted thoracoscopic IMA harvesting followed by total arterial off-pump anastomosis of the grafts through a left anterior 3-5 cm mini-thoracotomy. PCI will be performed via radial or femoral access according to local routine and is restricted to the RCA.

Multivessel hybrid coronary revascularization (HCR)

OPCAB will be performed as per clinical routine at each center through a median sternotomy. IMA harvesting (pedicled or skeletonised) follows each center's routine. An anaortic, total arterial strategy with a LIMA-LAD graft and complete revascularisation is obliged.

Off-pump coronary artery bypass grafting (OPCAB)

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with three-vessel disease (either angiographic stenoses \>70% or a fractional flow reserve value ≤0.80)
  • Left main diameter stenosis ≥50% or a left main intravascular ultrasound minimal luminal area of ≤4.5 mm2 or fractional flow reserve value ≤0.80 combined with significant CAD of the right coronary artery

You may not qualify if:

  • A potential participant who meets any of the following criteria will be excluded from participation in this study:
  • Age \< 18 or \> 85 years
  • Chronic total occlusion of the RCA
  • In-stent RCA restenosis
  • RCA stenosis with high-risk clinical features requiring urgent PCI or surgical revasculari-zation.
  • Reverse hybrid coronary revascularization, defined as PCI-RCA followed by surgical re-vascularization.
  • Acute cardiac ischemia necessitating immediate intervention.
  • EF \< 30 %
  • eGFR \< 30 ml/min
  • Indication for concomitant cardiac surgery (e.g. valve or arrhythmia surgery) or non-cardiac surgery
  • Previous thoracic or cardiac surgery, mediastinal irradiation, significant trauma to the chest
  • Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure) or cancer.
  • Hemodynamically significant left subclavian stenosis
  • Severe chest wall deformities
  • History of pericarditis
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University Hospitals Leuven

Leuven, Vlaams Brabant, 3000, Belgium

Location

Catharina Hospital Eindhoven

Eindhoven, Eindhoven, 5623 EJ, Netherlands

Location

Related Publications (30)

  • van Steenbergen GJ, Schulz DN, Slingerland SR, Tonino PA, Soliman-Hamad MA, Dekker L, van Veghel D. Introduction of a New Method to Monitor Patient-Relevant Outcomes and Costs: Using a Quality Improvement Project in Transcatheter Aortic Valve Implantation Care as an Example. Qual Manag Health Care. 2023 Oct-Dec 01;32(4):247-256. doi: 10.1097/QMH.0000000000000401. Epub 2023 Mar 16.

    PMID: 36940366BACKGROUND
  • Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Thygesen K, Alpert JS, White HD; Biomarker Subcommittee; Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA; ECG Subcommittee; Chaitman BR, Clemmensen PM, Johanson P, Hod H; Imaging Subcommittee; Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ; Classification Subcommittee; Fox KA, Atar D, Newby LK, Galvani M, Hamm CW; Intervention Subcommittee; Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J; Trials & Registries Subcommittee; Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML; Trials & Registries Subcommittee; Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G; Trials & Registries Subcommittee; Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D; Trials & Registries Subcommittee; Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG); Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Document Reviewers; Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012 Oct 16;60(16):1581-98. doi: 10.1016/j.jacc.2012.08.001. Epub 2012 Sep 5. No abstract available.

    PMID: 22958960BACKGROUND
  • Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264. doi: 10.1016/j.jacc.2018.08.1038. Epub 2018 Aug 25. No abstract available.

    PMID: 30153967BACKGROUND
  • Modrau IS, Nielsen PH, Nielsen DV, Christiansen EH, Hoffmann T, Parner ET, Benhassen LL. Outcome of hybrid compared to conventional revascularization in multivessel coronary artery disease. Scand Cardiovasc J. 2020 Dec;54(6):376-382. doi: 10.1080/14017431.2020.1821910. Epub 2020 Sep 30.

    PMID: 32998590BACKGROUND
  • Halkos ME, Ford L, Peterson D, Bluestein SM, Liberman HA, Kilgo P, Puskas JD, Guyton RA, Chowdhury R. The impact of hybrid coronary revascularization on hospital costs and reimbursements. Ann Thorac Surg. 2014 May;97(5):1610-5; discussion 1615-6. doi: 10.1016/j.athoracsur.2014.01.047. Epub 2014 Mar 15.

    PMID: 24636706BACKGROUND
  • Gianoli M, de Jong AR, van der Harst P, van der Kaaij NP, Jacob KA, Suyker WJL. Cost Analysis of Robot-Assisted Versus On-Pump and Off-Pump Coronary Artery Bypass Grafting: A Single-Center Surgical and 30-Day Outcomes Comparison. Innovations (Phila). 2024 Jul-Aug;19(4):416-424. doi: 10.1177/15569845241269312. Epub 2024 Sep 12.

    PMID: 39267423BACKGROUND
  • Michael Porter, Thomas Lee. The Strategy That Will Fix Healthcare. The Magazine.

    BACKGROUND
  • Zhang S, Li P, Li G, Yan Y, Sun T, Lin J, Zhang C, Liu S, Qu Z, You B. Generalized hybrid coronary revascularization vs. conventional off-pump coronary artery bypass grafting for multivessel coronary artery disease. Front Cardiovasc Med. 2025 Feb 21;12:1459072. doi: 10.3389/fcvm.2025.1459072. eCollection 2025.

    PMID: 40060966BACKGROUND
  • Harskamp RE, Vassiliades TA, Mehta RH, de Winter RJ, Lopes RD, Xian Y, Peterson ED, Puskas JD, Halkos ME. Comparative Effectiveness of Hybrid Coronary Revascularization vs Coronary Artery Bypass Grafting. J Am Coll Surg. 2015 Aug;221(2):326-34.e1. doi: 10.1016/j.jamcollsurg.2015.03.012. Epub 2015 Mar 20.

    PMID: 25899734BACKGROUND
  • Patel PM, Arrington RL, Jonsson A, Wei JW, Binongo J, Devireddy C, Nicholson W, Jaber W, Rinfret S, Halkos ME. Advancing the Treatment Paradigm for Multivessel Coronary Artery Disease: Hybrid Coronary Revascularization. Innovations (Phila). 2025 Jan-Feb;20(1):57-64. doi: 10.1177/15569845241311292. Epub 2025 Feb 2.

    PMID: 39894999BACKGROUND
  • Qu W, Wei J, Binongo JN, et al. Ischemic Heart Disease HYBRID CORONARY REVASCULARIZATION PROVIDES COMPARABLE LONG-TERM OUTCOMES TO CORONARY ARTERY BYPASS GRAFTING FOR PATIENTS WITH TWO-VESSEL CORONARY DISEASE. Vol 83.; 2024.

    BACKGROUND
  • Xia Y, Katz AN, Forest SJ, Pyo RT, Greenberg MA, DeRose JJ Jr. Hybrid Coronary Revascularization has Improved Short-term Outcomes but Worse Mid-term Reintervention Rates Compared to CABG: A Propensity Matched Analysis. Innovations (Phila). 2017 May/Jun;12(3):174-179. doi: 10.1097/IMI.0000000000000376.

    PMID: 28549028BACKGROUND
  • Harskamp RE, Puskas JD, Tijssen JG, Walker PF, Liberman HA, Lopes RD, Vassiliades TA, Peterson ED, Halkos ME. Comparison of hybrid coronary revascularization versus coronary artery bypass grafting in patients>/=65 years with multivessel coronary artery disease. Am J Cardiol. 2014 Jul 15;114(2):224-9. doi: 10.1016/j.amjcard.2014.04.028. Epub 2014 May 2.

    PMID: 24878119BACKGROUND
  • Harskamp RE, Bagai A, Halkos ME, Rao SV, Bachinsky WB, Patel MR, de Winter RJ, Peterson ED, Alexander JH, Lopes RD. Clinical outcomes after hybrid coronary revascularization versus coronary artery bypass surgery: a meta-analysis of 1,190 patients. Am Heart J. 2014 Apr;167(4):585-92. doi: 10.1016/j.ahj.2014.01.006. Epub 2014 Jan 29.

    PMID: 24655709BACKGROUND
  • Lowenstern A, Wu J, Bradley SM, Fanaroff AC, Tcheng JE, Wang TY. Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry. Am Heart J. 2019 Sep;215:167-177. doi: 10.1016/j.ahj.2019.06.014. Epub 2019 Jun 28.

    PMID: 31349108BACKGROUND
  • Gortzen Q, Sampon F, Timmermans N, Woorst JT, Akca F. Endoscopic-Assisted Multivessel Off-Pump Coronary Artery Bypass Grafting: Experience of the First 100 Procedures. J Chest Surg. 2025 Jan 5;58(1):21-30. doi: 10.5090/jcs.24.080. Epub 2024 Nov 18.

    PMID: 39552038BACKGROUND
  • Sampon F, Ter Woorst J, Dekker L, Akca F. Thoracoscopic-assisted, minimally invasive versus off-pump bypass grafting for single vessel coronary artery disease - A propensity matched analysis. Int J Cardiol. 2024 Aug 15;409:132175. doi: 10.1016/j.ijcard.2024.132175. Epub 2024 May 14.

    PMID: 38754586BACKGROUND
  • Akca F. Thoracoscopic (non-robotic) harvesting of bilateral internal mammary artery grafts. Multimed Man Cardiothorac Surg. 2023 Nov 15;2023. doi: 10.1510/mmcts.2023.069.

    PMID: 37965985BACKGROUND
  • Chen S, Karmpaliotis D, Redfors B, Shlofmitz E, Ben-Yehuda O, Crowley A, Mehdipoor G, Puskas JD, Kandzari DE, Banning AP, Morice MC, Taggart DP, Sabik JF 3rd, Serruys PW, Kappetein AP, Stone GW. Does an occluded RCA affect prognosis in patients undergoing PCI or CABG for left main coronary artery disease? Analysis from the EXCEL trial. EuroIntervention. 2019 Aug 9;15(6):e531-e538. doi: 10.4244/EIJ-D-19-00263.

    PMID: 31186220BACKGROUND
  • Sajja LR, Mannam G. Internal thoracic artery: anatomical and biological characteristics revisited. Asian Cardiovasc Thorac Ann. 2015 Jan;23(1):88-99. doi: 10.1177/0218492314523629. Epub 2014 Feb 11.

    PMID: 24585304BACKGROUND
  • Royse AG, Brennan AP, Ou-Young J, Pawanis Z, Canty DJ, Royse CF. 21-Year Survival of Left Internal Mammary Artery-Radial Artery-Y Graft. J Am Coll Cardiol. 2018 Sep 18;72(12):1332-1340. doi: 10.1016/j.jacc.2018.06.064.

    PMID: 30213324BACKGROUND
  • Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, Domanski MJ, Farkouh ME, Flather M, Fuster V, Hlatky MA, Holm NR, Hueb WA, Kamalesh M, Kim YH, Makikallio T, Mohr FW, Papageorgiou G, Park SJ, Rodriguez AE, Sabik JF 3rd, Stables RH, Stone GW, Serruys PW, Kappetein AP. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018 Mar 10;391(10124):939-948. doi: 10.1016/S0140-6736(18)30423-9. Epub 2018 Feb 23.

    PMID: 29478841BACKGROUND
  • Fearon WF, Zimmermann FM, De Bruyne B, Piroth Z, van Straten AHM, Szekely L, Davidavicius G, Kalinauskas G, Mansour S, Kharbanda R, Ostlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Angeras O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstrom T, Christiansen EH, Tonino PAL, Reardon MJ, Lu D, Ding VY, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ; FAME 3 Investigators. Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med. 2022 Jan 13;386(2):128-137. doi: 10.1056/NEJMoa2112299. Epub 2021 Nov 4.

    PMID: 34735046BACKGROUND
  • Holm NR, Makikallio T, Lindsay MM, Spence MS, Erglis A, Menown IBA, Trovik T, Kellerth T, Kalinauskas G, Mogensen LJH, Nielsen PH, Niemela M, Lassen JF, Oldroyd K, Berg G, Stradins P, Walsh SJ, Graham ANJ, Endresen PC, Frobert O, Trivedi U, Anttila V, Hildick-Smith D, Thuesen L, Christiansen EH; NOBLE investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet. 2020 Jan 18;395(10219):191-199. doi: 10.1016/S0140-6736(19)32972-1. Epub 2019 Dec 23.

    PMID: 31879028BACKGROUND
  • Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012 Dec 20;367(25):2375-84. doi: 10.1056/NEJMoa1211585. Epub 2012 Nov 4.

    PMID: 23121323BACKGROUND
  • Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009 Mar 5;360(10):961-72. doi: 10.1056/NEJMoa0804626. Epub 2009 Feb 18.

    PMID: 19228612BACKGROUND
  • Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS; Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20.

    PMID: 37471501BACKGROUND
  • Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177. No abstract available.

    PMID: 39210710BACKGROUND
  • World Health Organization. The top 10 causes of death. Published August 7, 2024. Accessed July 16, 2025. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

    BACKGROUND
  • Gortzen Q, Sampon F, Timmermans N, Ter Woorst J, Akca F. Endoscopic-assisted, minimally invasive versus sternotomy total arterial multivessel bypass grafting. Interdiscip Cardiovasc Thorac Surg. 2024 Nov 6;39(5):ivae187. doi: 10.1093/icvts/ivae187.

    PMID: 39540774BACKGROUND

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Ferdi Akca, MD, PhD

    Catharina Ziekenhuis Eindhoven

    PRINCIPAL INVESTIGATOR
  • Wouter Oosterlinck, Prof. Dr. MD, PhD

    Universitaire Ziekenhuizen KU Leuven

    STUDY CHAIR
  • Pim Tonino, Prof. Dr. MD, PhD

    Catharina Ziekenhuis Eindhoven

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Dual center, superiority, randomized controlled trial.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 3, 2025

First Posted

January 2, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

May 1, 2029

Study Completion (Estimated)

May 1, 2034

Last Updated

January 2, 2026

Record last verified: 2025-12

Locations